CAPR
NASDAQ · Biotechnology
Capricor Therapeutics Inc
$9.06
-0.36 (-3.82%)
CAPR News6 articles
Capricor's FDA Delay Trims Stock to Cash-Adjusted Bet
Capricor shares dropped 8% after the FDA postponed its decision on deramiocel, leaving a slim premium above cash. Analyst targets remain sharply divided.
Capricor Shares Jump as FDA Reviews New Duchenne Data; PDUFA Date Looms
Capricor shares rose 51.7% after the FDA agreed to review new 24-month data for deramiocel, but the stock remains far below its July peak as the Aug. 22 decision date approaches.
Capricor Therapeutics Plunges 67% on FDA Concerns Over Deramiocel Efficacy
Capricor Therapeutics shares plummeted 67% after FDA staff flagged concerns about deramiocel's efficacy data, wiping out $766 million in market value ahead of a key advisory committee vote.
BioCardia Surges on FDA Minutes Showing CardiAMP Trial Can Support PMA
BioCardia shares surged 52% to $1.40 after FDA meeting minutes confirmed its CardiAMP HF II trial may support a PMA for heart-failure cell therapy, bucking a weak biotech sector.
Market Movers: RELX, Capricor, and Global Tensions Shape Trading
RELX drops 8.8% in a week, Capricor soars 387% annually, US-Iran tensions drive crude oil volatility, and other key market movers on May 10, 2026.
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.